Abstract: Objective To study the toxicity of oral administration of rats in different extractions of psoralen, and provide a safe basis for its clinical application. Method One hundred and twelve SD rats were divided into 8 groups according to gender and body weight: control group, psoralen drug group, high and low dose group of osmotic lower osmosis, high osmium osmium permeation, In the low-dose group, the high-and low-dose group of psoralen osmosis drug slag (the dose of the crude drug group was 3 g/kg (raw dose), and the high and low doses of other drug-administered groups were 6 and 3 g/kg, respectively. (raw dose)), 14 in each group. After 4 weeks of continuous administration, after the end of the drug-administered period, the rats were fasted for 12 hours, and blood was taken for blood biochemical indicators. The organ was weighed and the organ coefficient was calculated and the MDA in the liver tissue was determined. Histopathological examination was performed. Result Compared with the control group, the liver organ coefficient, ALP and MDA of the psoralen crude drug group were significantly increased, the thymus organ coefficient and T-AOC were significantly decreased; the visceral osmosis liquid lower layer extract group was characterized by liver organ coefficient, T-AOC and ALT were significantly increased; the liver organ coefficient and MDA of the high-dose group of psoralen and sputum slag were significantly increased while the T-AOC value of female rats was significantly decreased, while the low-dose group of drug residue did not have liver or kidney. The toxicity index was significant; there was no significant difference in the upper layer of psoralen permeation. Conclusion The safety of the upper osmotic liquid of psoralen is better than that of the lower osmotic liquid of psoralen. However, based on the result of the determination of active ingredients, the lower layer of osmotic solution is more suitable for the drug site.

Key words: Psoralen, hepatotoxicity, different extractions

摘要： 目的 研究不同提取物的补骨脂大鼠口服给药的毒性，为其临床应用提供安全依据。方法 112只SD大鼠雌雄各半，按性别、体质量随机分为8组：对照组，补骨脂生药组，补骨脂下层渗漉液高、低剂量组，补骨脂上层渗漉液高、低剂量组，补骨脂渗漉药渣高、低剂量组[生药组剂量(生药量)为3 g/kg体质量，其他给药组高、低剂量(生药量)均分别为6和3 g/kg体质量]，每组14只。连续给药4周，给药周期结束后，禁食不禁水12 h，取血进行相关血生化指标检测，解剖取脏器称重计算脏器系数并测定肝脏组织中MDA，组织病理学检查。结果 与对照组相比，补骨脂生药组肝脏脏器系数、ALP、MDA显著升高，胸腺脏器系数、T-AOC显著降低；补骨脂下层渗漉液剂量组肝脏脏器系数、T-AOC、ALT显著升高；补骨脂渗漉药渣高剂量组肝脏脏器系数、MDA显著升高而雌性大鼠T-AOC值显著降低，药渣低剂量组并没有明显的肝、肾毒性；补骨脂上层渗漉液组无显著差异。结论 补骨脂上层渗漉液的安全性优于补骨脂下层渗漉液，但基于有效成分测定结果提示，下层渗漉液更合适入药。

关键词: 补骨脂, 肝毒性, 不同提取物